Clinical trial · Observational
SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Recently technology has been developed at the Wellcome Sanger Institute to allow clusters of cells with mutations to be detected in normal and diseased tissues. The researchers wish to determine how the number and nature of these mutant cell clusters change in response to treatments given to cancer patients (such as chemotherapy, radiotherapy, immunotherapy, and drugs targeted at specific mutations in tumours). As such the researchers wish to collect research samples of blood, cheek cells (via swabs) and urine from adult cancer patients receiving the above-mentioned treatments as part of their standard care. The researchers also wish to access any leftover tissue following surgery that is undertaken as part of these patient's treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Somatic Mutation | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Discussing study | Other | — | UNRESOLVED |
| sample collection | Other | — | UNRESOLVED |
| Seeking consent | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Non melanoma skin cancer
- description
- Skin cancer patients receiving Immune checkpoint immunotherapy.
- interventionNames
- Other: sample collection
- Other: Discussing study
- Other: Seeking consent
- label
- Head and Neck Cancer
- description
- Head and Neck cancer patients receiving chemoradiotherapy.
- interventionNames
- Other: sample collection
- Other: Discussing study
- Other: Seeking consent
Primary outcomes (2)
- measure
- To measure the frequency of acquired (somatic) mutations
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Male or Female * Due to commence systemic treatment for histologically confirmed cancer at a - participating site * Age over 18 years * Able to give informed consent. * Able to give urine, blood and cheek swab samples on two occasions. * Likely to complete 3 months of treatment Exclusion Criteria: * Anyone outside of the inclusion criteria plus individuals who Lack the capacity to provide informed consent and those who do not have a good command of the English language. * Any participant who is known to have Hep B, Hep C or HIV
References
Publications (0)
Data not yet available